Neurotech Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
164
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$550M
Neurotech General Information
Description
Developer of encapsulated cell-based therapies designed for the treatment of chronic eye diseases. The company's platform uses genetically engineered cell implants and semi-permeable capsule technology to deliver therapeutic proteins continuously, protect photoreceptors, and provide long-acting retinal treatment, helping ophthalmologists and retina practices slow the progression of vision loss in patients with macular telangiectasia type 2.
Contact Information
Website
www.neurotechpharmaceuticals.com(Operating Subsidiary)
Corporate Office
- 900 Highland Corporate Drive
- Building 1
- Cumberland, RI 02864
- United States
Corporate Office
- 900 Highland Corporate Drive
- Building 1
- Cumberland, RI 02864
- United States
Neurotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 20-Oct-2026 | $550M | Completed | Clinical Trials - Phase 3 | ||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 9. Grant | 01-Sep-2018 | Completed | Clinical Trials - Phase 3 | |||
| 8. Secondary Transaction - Private | 15-Aug-2016 | Completed | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC (Series F) | 28-Mar-2014 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series E) | 28-Jun-2013 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC (Series D) | 22-Dec-2010 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C) | 17-Mar-2010 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series B) | 16-Nov-2006 | $35M | $48.7M | Completed | Clinical Trials - Phase 3 | |
| 2. Early Stage VC (Series A) | 24-Nov-2003 | $13.7M | $13.7M | Completed | Clinical Trials - Phase 3 |
Neurotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B-2 | 5,682,096 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 3.84% |
| Series B-1 | 8,823,406 | $0.000100 | 8% | $1.03 | $1.03 | 1x | $1.03 | 5.96% |
Neurotech Comparisons
Industry
Financing
Details
Neurotech Competitors (9)
One of Neurotech’s 9 competitors is ONL Therapeutics, a Venture Capital-Backed company based in Ann Arbor, MI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Kala Bio | Formerly VC-backed | Arlington, MA | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| Ocular Therapeutix | Formerly VC-backed | Bedford, MA |
Neurotech Patents
Neurotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20060277220-A1 | Security data redaction | Active | 28-Mar-2005 | ||
| US-8086615-B2 | Security data redaction | Inactive | 28-Mar-2005 | ||
| AU-2001259422-A1 | Immortalized lines of endothelial brain cells and therapeutic application thereof | Inactive | 03-May-2000 | ||
| WO-2001083716-A2 | Immortalized lines of endothelial brain cells and therapeutic application thereof | Inactive | 03-May-2000 | ||
| WO-2001083716-A3 | Immortalized lines of endothelial brain cells and therapeutic application thereof | Inactive | 03-May-2000 | C12N5/069 |
Neurotech Signals
Neurotech Former Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| Amundi Alpha Associates | Fund of Funds | Minority | ||
| Apax Partners | PE/Buyout | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Burrill & Co | Merchant Banking Firm | Minority |
Neurotech FAQs
-
When was Neurotech founded?
Neurotech was founded in 2002.
-
Where is Neurotech headquartered?
Neurotech is headquartered in Cumberland, RI.
-
What is the size of Neurotech?
Neurotech has 164 total employees.
-
What industry is Neurotech in?
Neurotech’s primary industry is Drug Discovery.
-
Is Neurotech a private or public company?
Neurotech is a Private company.
-
What is the current valuation of Neurotech?
The current valuation of Neurotech is .
-
What is Neurotech’s current revenue?
The current revenue for Neurotech is .
-
How much funding has Neurotech raised over time?
Neurotech has raised $111M.
-
Who are Neurotech’s investors?
3i Group, Amundi Alpha Associates, Apax Partners, Atlas Venture, and Burrill & Co are 5 of 21 investors who have invested in Neurotech.
-
Who are Neurotech’s competitors?
ONL Therapeutics, Foventa Therapeutics, Kala Bio, EyePoint, and Ocular Therapeutix are some of the 9 competitors of Neurotech.
-
When was Neurotech acquired?
Neurotech was acquired on 20-Oct-2026.
-
Who acquired Neurotech?
Neurotech was acquired by Alcon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process